BBLG Key Statistics, Chart & Performance
The current stock price of BBLG is 1.54 USD. In the past month the price decreased by -12.99%. In the past year, price decreased by -74.84%.
BBLG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.3 | 389.14B | ||
| AMGN | AMGEN INC | 14.66 | 172.70B | ||
| GILD | GILEAD SCIENCES INC | 14.44 | 146.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.85 | 113.87B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.96 | 80.22B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.06 | 52.56B | ||
| INSM | INSMED INC | N/A | 37.36B | ||
| NTRA | NATERA INC | N/A | 32.77B | ||
| BIIB | BIOGEN INC | 10.43 | 25.62B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.56 | 21.09B | ||
| INCY | INCYTE CORP | 15.86 | 19.98B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.28B |
Related stock screener links
About BBLG
Company Profile
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Company Info
BONE BIOLOGICS CORP
2 Burlington Woods Dr Ste 100
Burlington MASSACHUSETTS US
Employees: 2
Phone: 17815524452
BONE BIOLOGICS CORP / BBLG FAQ
Can you describe the business of BONE BIOLOGICS CORP?
Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Can you provide the latest stock price for BONE BIOLOGICS CORP?
The current stock price of BBLG is 1.54 USD.
Does BBLG stock pay dividends?
BBLG does not pay a dividend.
How is the ChartMill rating for BONE BIOLOGICS CORP?
BBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BONE BIOLOGICS CORP (BBLG) stock traded?
BBLG stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for BONE BIOLOGICS CORP?
BONE BIOLOGICS CORP (BBLG) operates in the Health Care sector and the Biotechnology industry.
What is the outstanding short interest for BONE BIOLOGICS CORP?
The outstanding short interest for BONE BIOLOGICS CORP (BBLG) is 3.02% of its float.
BBLG Technical Analysis
BBLG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BBLG. No worries on liquidiy or solvency for BBLG as it has an excellent financial health rating, but there are worries on the profitability.
BBLG Financial Highlights
Over the last trailing twelve months BBLG reported a non-GAAP Earnings per Share(EPS) of -7.3. The EPS increased by 82.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.13% | ||
| ROE | -65.59% | ||
| Debt/Equity | 0 |
BBLG Forecast & Estimates
7 analysts have analysed BBLG and the average price target is 22.7 USD. This implies a price increase of 1373.7% is expected in the next year compared to the current price of 1.54.